MTOR and central nervous system cancer: However, when combined with temozolomide, an alkylating agent, NVP-BEZ235 has been shown to downregulate PI3K/mTOR pathways, in glioma cells (158) but in combination with AZD6244, a MAP kinase inhibitor, NVP-BEZ235 significantly reduced radio-sensitization of irradiated lung cancer and glioma cells (144).